The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.
While Cynvenio will still perform testing in its own lab right now, the firm's CEO said that interested labs could move the technology in house in the future if they desire.
The firm has launched a yearly subscription program that includes quarterly blood tests to look for genetic and proteomic signs of metastasis or cancer recurrence.
The combination test will allow clinicians to analyze breast cancer patients for germline hereditary cancer markers at the same time as they search their blood for driver mutations.
Milenia will exclusively offer the test to patients through its network of 12 diagnostic centers in Mexico, and will also make future assays available.
The results indicate that while blood-based assays can be useful, tissue biopsies should remain the gold standard when available, said one of the study authors.
The study will join Cynvenio's ClearID test with ATGen's NK Vue test to detect cancer recurrence in previously treated triple-negative breast cancer patients.
The firm said that theUSfederal government recognizes the CAP accreditation program as being equal to or more stringent than its own inspection program.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.